0001127602-22-019858.txt : 20220728 0001127602-22-019858.hdr.sgml : 20220728 20220728160323 ACCESSION NUMBER: 0001127602-22-019858 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220727 FILED AS OF DATE: 20220728 DATE AS OF CHANGE: 20220728 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeLong Mark Jeffrey CENTRAL INDEX KEY: 0001856078 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 221115199 MAIL ADDRESS: STREET 1: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-07-27 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001856078 DeLong Mark Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Senior Vice President Common Stock 2022-07-27 4 M 0 5000 15.52 A 34250 D Common Stock 2022-07-27 4 S 0 5000 57.00 D 29250 D Stock Option (Right to Buy) 15.52 2022-07-27 4 M 0 5000 0 D 2028-02-04 Common Stock 5000 25000 D This is a scheduled exercise and sale from an established 10B5-1 trading plan. This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service. /s/ David Watson, attorney-in-fact for Mark Delong 2022-07-28